Maraviroc
As of the edition of 20 October 2026, Maraviroc is a small molecule: marketed, first approved in 2007 (US); acts on CCR5; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2008
- Kind
- Small molecule
- Brand name
- Selzentry
- First approved
- 6 August 2007 (US)
- Approvals on record
- 10 in 5 regions
- Holder of the most recent approval
- GSK; 4 holders in all
- Registered trials
- 119, 20 stopped early
- Disease areas
- Infections; Immune system; Urinary and reproductive; Cancer; Blood and lymph; Digestive system
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B and 1 company on route A because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Maraviroc.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Companies on route A for this drug
In the product1 company is on route A because of Maraviroc.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CCR5 | C-C chemokine receptor type 5 | P51681 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 18 | 13 | 0 | 2 |
| Phase 1 | 27 | 23 | 0 | 4 |
| Phase 2 | 30 | 18 | 4 | 5 |
| Phase 3 | 18 | 14 | 0 | 4 |
| Phase 4 | 26 | 18 | 1 | 5 |
| All trials | 119 |